These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
884 related articles for article (PubMed ID: 29282600)
1. Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Patients with Peritoneal Metastases from Endometrial Cancer. Cornali T; Sammartino P; Kopanakis N; Christopoulou A; Framarino Dei Malatesta M; Efstathiou E; Spagnoli A; Ciardi A; Biacchi D; Spiliotis J Ann Surg Oncol; 2018 Mar; 25(3):679-687. PubMed ID: 29282600 [TBL] [Abstract][Full Text] [Related]
2. Is Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy Justified for Biphasic Variants of Peritoneal Mesothelioma? Outcomes from the Peritoneal Surface Oncology Group International Registry. Votanopoulos KI; Sugarbaker P; Deraco M; Morris D; Glehen O; Elias D; De Simone M; Robella M; Heyd B; Kusamura S; Baratti D; Chouliaras K; Russell G; Shen P; Levine EA; Ann Surg Oncol; 2018 Mar; 25(3):667-673. PubMed ID: 29260418 [TBL] [Abstract][Full Text] [Related]
3. Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent or progressive diffuse malignant peritoneal mesothelioma: clinicopathologic characteristics and survival outcome. Ihemelandu C; Bijelic L; Sugarbaker PH Ann Surg Oncol; 2015 May; 22(5):1680-5. PubMed ID: 25120250 [TBL] [Abstract][Full Text] [Related]
4. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Gastric Cancer with Peritoneal Carcinomatosis: Multicenter Study of Spanish Group of Peritoneal Oncologic Surgery (GECOP). Manzanedo I; Pereira F; Rihuete Caro C; Pérez-Viejo E; Serrano Á; Gutiérrez Calvo A; Regueira FM; Casado-Adam Á; Cascales-Campos PA; Arteaga X; García-Fadrique A; Gómez Sanz R; López García A; Zozaya G; Arjona Á; Gil Martínez J Ann Surg Oncol; 2019 Aug; 26(8):2615-2621. PubMed ID: 31115852 [TBL] [Abstract][Full Text] [Related]
5. Hyperthermic intraperitoneal chemotherapy plus simultaneous versus staged cytoreductive surgery for gastric cancer with occult peritoneal metastasis. Wu X; Li Z; Li Z; Jia Y; Shan F; Ji X; Bu Z; Zhang L; Wu A; Ji J J Surg Oncol; 2015 Jun; 111(7):840-7. PubMed ID: 25864884 [TBL] [Abstract][Full Text] [Related]
6. Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with recurrent peritoneal carcinomatosis. Vassos N; Förtsch T; Aladashvili A; Hohenberger W; Croner RS World J Surg Oncol; 2016 Feb; 14(1):42. PubMed ID: 26912149 [TBL] [Abstract][Full Text] [Related]
7. Impact of Synchronous Versus Metachronous Onset of Colorectal Peritoneal Metastases on Survival Outcomes After Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC): A Multicenter, Retrospective, Observational Study. Hentzen JEKR; Rovers KP; Kuipers H; van der Plas WY; Been LB; Hoogwater FJH; van Ginkel RJ; Hemmer PHJ; van Dam GM; de Hingh IHJT; Kruijff S Ann Surg Oncol; 2019 Jul; 26(7):2210-2221. PubMed ID: 30877495 [TBL] [Abstract][Full Text] [Related]
8. Repeat Cytoreductive Surgery-Hyperthermic Intraperitoneal Chemoperfusion is Feasible and Offers Survival Benefit in Select Patients with Peritoneal Metastases. Choudry HA; Bednar F; Shuai Y; Jones HL; Pai RK; Pingpank JF; Ahrendt SS; Holtzman MP; Zeh HJ; Bartlett DL Ann Surg Oncol; 2019 May; 26(5):1445-1453. PubMed ID: 30825033 [TBL] [Abstract][Full Text] [Related]
9. Treatment of Isolated Peritoneal Recurrences in Patients with Colorectal Peritoneal Metastases Previously Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. van Eden WJ; Elekonawo FMK; Starremans BJ; Kok NFM; Bremers AJA; de Wilt JHW; Aalbers AGJ Ann Surg Oncol; 2018 Jul; 25(7):1992-2001. PubMed ID: 29671139 [TBL] [Abstract][Full Text] [Related]
10. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for managing peritoneal carcinomatosis from endometrial carcinoma: a single-center experience of 6 cases. Abu-Zaid A; Azzam AZ; AlOmar O; Salem H; Amin T; Al-Badawi IA Ann Saudi Med; 2014; 34(2):159-66. PubMed ID: 24894786 [TBL] [Abstract][Full Text] [Related]
11. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Baumgartner JM; Tobin L; Heavey SF; Kelly KJ; Roeland EJ; Lowy AM Ann Surg Oncol; 2015 May; 22(5):1716-21. PubMed ID: 25145504 [TBL] [Abstract][Full Text] [Related]
12. HIPEC and CRS in peritoneal metastatic gastric cancer - who really benefits? Hotopp T Surg Oncol; 2019 Mar; 28():159-166. PubMed ID: 30851894 [TBL] [Abstract][Full Text] [Related]
13. Extreme cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Outcomes from a single tertiary center. Berger Y; Aycart S; Mandeli JP; Heskel M; Sarpel U; Labow DM Surg Oncol; 2015 Sep; 24(3):264-9. PubMed ID: 26143715 [TBL] [Abstract][Full Text] [Related]
14. [Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy]. Yu Y; Li XB; Lin YL; Ma R; Ji ZH; Zhang YB; An SL; Liu G; Yang XJ; Li Y Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):230-239. PubMed ID: 34645167 [No Abstract] [Full Text] [Related]
15. Peritoneal cancer index (PCI) based patient selecting strategy for complete cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in gastric cancer with peritoneal metastasis: A single-center retrospective analysis of 125 patients. Ji ZH; Yu Y; Liu G; Zhang YB; An SL; Li B; Li XB; Yan GJ; Li Y Eur J Surg Oncol; 2021 Jun; 47(6):1411-1419. PubMed ID: 33293213 [TBL] [Abstract][Full Text] [Related]
16. PCI is Not Predictive of Survival After Complete CRS/HIPEC in Peritoneal Dissemination from High-Grade Appendiceal Primaries. Votanopoulos KI; Bartlett D; Moran B; Haroon CM; Russell G; Pingpank JF; Ramalingam L; Kandiah C; Chouliaras K; Shen P; Levine EA Ann Surg Oncol; 2018 Mar; 25(3):674-678. PubMed ID: 29288288 [TBL] [Abstract][Full Text] [Related]
17. Surgical and oncological outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy at a nonacademic center: 25-year experience. Nikiforchin A; Gushchin V; King MC; Baron E; Nieroda C; Sittig M; Sardi A J Surg Oncol; 2021 Mar; 123(4):1030-1044. PubMed ID: 33524164 [TBL] [Abstract][Full Text] [Related]
18. Primary Tumor Sidedness is Predictive of Survival in Colon Cancer Patients Treated with Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy: A US HIPEC Collaborative Study. Kotha NV; Baumgartner JM; Veerapong J; Cloyd JM; Ahmed A; Grotz TE; Leiting JL; Fournier K; Lee AJ; Dineen SP; Dessureault S; Clarke C; Mogal H; Zaidi MY; Russell MC; Patel SH; Sussman JJ; Dhar V; Lambert LA; Hendrix RJ; Abbott DE; Pokrzywa C; Lafaro K; Lee B; Greer JB; Fackche N; Lowy AM; Kelly KJ Ann Surg Oncol; 2019 Jul; 26(7):2234-2240. PubMed ID: 31016486 [TBL] [Abstract][Full Text] [Related]
19. Peritoneal Carcinomatosis of Urachus Origin Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): An International Registry of 36 Patients. Mercier F; Passot G; Villeneuve L; Levine EA; Yonemura Y; Goéré D; Sugarbaker PH; Marolho C; Bartlett DL; Glehen O; Ann Surg Oncol; 2018 Apr; 25(4):1094-1100. PubMed ID: 29238881 [TBL] [Abstract][Full Text] [Related]
20. Predictive and prognostic survival factors in peritoneal carcinomatosis from appendiceal cancer after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Jimenez W; Sardi A; Nieroda C; Sittig M; Milovanov V; Nunez M; Aydin N; Gushchin V Ann Surg Oncol; 2014 Dec; 21(13):4218-25. PubMed ID: 24986239 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]